Page last updated: 2024-12-10

prostaglandin f3alpha

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prostaglandin F3alpha : A prostaglandin Falpha that is prosta-5,13,17-trien-1-oic acid carrying three hydroxy substituents at positions 9alpha, 11alpha and 15. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280940
CHEBI ID36075
SCHEMBL ID10486308
MeSH IDM0105658

Synonyms (23)

Synonym
(5z,13e,15s,17z)-9alpha,11alpha,15-trihydroxyprosta-5,13,17-trien-1-oic acid
745-64-2
CHEBI:36075
prosta-5,13,17-trien-1-oic acid, 9,11,15-trihydroxy-, (5z,9alpha,11alpha,13e,15s,17z)-
prostaglandin f3 alpha
LMFA03010138
pgf3alpha
9s,11r,15s-trihydroxy-5z,13e,17z-prostatrienoic acid
prostaglandin f3alpha
C06476
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s,5z)-3-hydroxyocta-1,5-dienyl]cyclopentyl]hept-5-enoic acid
prosta-5,13,17-trien-1-oicacid, 9,11,15-trihydroxy-, (5z,9a,11a,13e,15s,17z)-
SCHEMBL10486308
prosta-5,13,17-trien-1-oic acid, 9,11,15-trihydroxy-, (5z,9.alpha.,11.alpha.,13e,15s,17z)-
pgf3.alpha.
prostaglandin f3.alpha.
prosta-5,13,17-trien-1-oicacid,9,11,15-trihydroxy-,(5z,9a,11a,13e,15s,17z)-
prostaglandin f3a
(5z,9alpha,11alpha,13e,15s,17z)-9,11,15-trihydroxy-prosta-5,13,17-trien-1-oate
(5z,9alpha,11alpha,13e,15s,17z)-9,11,15-trihydroxy-prosta-5,13,17-trien-1-oic acid
Q27104327
SR-01000946867-1
sr-01000946867
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostaglandins Falpha
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (27.27)18.7374
1990's2 (18.18)18.2507
2000's2 (18.18)29.6817
2010's4 (36.36)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]